Iovance Biotherapeutics Inc.

Company Snapshot

Founded: 2007

Entity Type: Public

Employees: 838

Region: U.S.

Revenue: $164.1 Millions

Revenue Year: 2024

Headquarter: U.S.

Key Geographics: North America, Europe

Corporate Address: 825 Industrial Road Suite 400, San Carlos California 94070 U.s. Tel. +1-650-260-7120 www.iovance.com

Company Overview

Iovance Biotherapeutics Inc. is a leading biotechnology company dedicated to revolutionizing cancer treatment through developing and commercializing novel cell therapies. Founded in 2007 and headquartered in San Carlos, California, Iovance is at the forefront of immuno-oncology, leveraging cutting-edge technologies to leverage the immune system’s potential in fighting cancer.

Iovance’s innovative approach is its proprietary Tumor-Infiltrating Lymphocyte (TIL) therapy platform. TIL therapy involves the isolation, expansion, and reinfusion of a patient’s tumor-infiltrating lymphocytes, immune cells naturally present within tumors and capable of recognizing and attacking cancer cells. By amplifying these potent anti-tumor immune cells outside the body and reintroducing them into the patient, Iovance aims to supercharge the immune response against cancer, leading to durable and potentially curative responses.

Financial Highlights (FY 2024)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member